A case report: cold hemagglutinin disease in a pancreatic and renal transplant patient

Publications

Share / Export Citation / Email / Print / Text size:

Immunohematology

American National Red Cross

Subject: Medical Laboratory Technology

GET ALERTS SUBSCRIBE

ISSN: 0894-203X
eISSN: 1930-3955

DESCRIPTION

8
Reader(s)
9
Visit(s)
0
Comment(s)
0
Share(s)

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue / page

Archive
Volume 37 (2021)
Volume 36 (2020)
Volume 35 (2019)
Volume 34 (2018)
Volume 33 (2017)
Volume 32 (2016)
Volume 31 (2015)
Volume 30 (2014)
Volume 29 (2013)
Volume 28 (2012)
Volume 27 (2011)
Volume 26 (2010)
Volume 25 (2009)
Volume 24 (2008)
Volume 23 (2007)
Volume 22 (2006)
Volume 21 (2005)
Volume 20 (2004)
Volume 19 (2003)
Volume 18 (2002)
Volume 17 (2001)
Volume 16 (2000)
Volume 15 (1999)
Volume 14 (1998)
Volume 13 (1997)
Volume 12 (1996)
Volume 11 (1995)
Volume 10 (1994)
Volume 9 (1993)
Volume 8 (1992)
Volume 7 (1991)
Volume 6 (1990)
Volume 5 (1989)
Volume 4 (1988)
Volume 3 (1987)
Related articles

VOLUME 4 , ISSUE 4 (December 1988) > List of articles

A case report: cold hemagglutinin disease in a pancreatic and renal transplant patient

Catherine Y. Beiting / Kathleen S. Larimore

Citation Information : Immunohematology. Volume 4, Issue 4, Pages 85-87, DOI: https://doi.org/10.21307/immunohematology-2019-1112

License : (Transfer of Copyright)

Published Online: 29-December-2020

ARTICLE

ABSTRACT

A 33-year-old white male, 30 days postpancreatic transplant, with a history of juvenile onset diabetes mellitus and previous renal transplant, appeared to have cold hemagglutinin disease (CHD). He was being treated for acute organ rejection and had received two units of red blood cells (RBCs) on postoperative day 11, at which time no serum antibodies were detectable. On postoperative day 30, serum studies showed an autoanti-I with a titer of 512 in 30 percent albumin at 4°C and a maximum thermal amplitude of 37°C. The patie  nt had a weakly positive direct antiglobulin test (DAT) with only complement detectable on the red cells. The patient recovered spontaneously. The etiology of the CHD is unclear. The use of cyclosporin-A, OKT3 monoclonal antibody, and anti-thymocyte globulin (ATG) to treat acute rejection could have played a part.

You don't have 'Full Text' access of this article.

Purchase Article Subscribe Journal Share